ScripsAmerica Launches RapiMed To Beat Tylenol Meltaways
This article was originally published in The Tan Sheet
ScripsAmerica Inc.’s new RapiMed line of orally dissolving pediatric painkillers seeks to beat McNeil Consumer Healthcare’s Tylenol Meltaways’ return to the market and steal share from private label by promising to melt faster, taste better and cost less. The products also address FDA dosing concerns and target Hispanic shoppers.
You may also be interested in...
McNeil Consumer Healthcare recalls an Infants’ Tylenol product that returned to market in November, after receiving consumer complaints about a problem with the SimpleMeasure dosing device system. The recall marks a misstep in the J&J subsidiary’s comeback from OTC quality control issues.
FDA will wield tight oversight of Johnson & Johnson subsidiary McNeil Consumer Healthcare's OTC manufacturing operations under a consent decree filed after the firm's quality-control changes failed to satisfy the agency.
OTC drug manufacturers must consider a dosing device as a primary element of liquid product packaging to improve consumer safety through proper dosing, industry stakeholders say